Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2)

被引：0
|
作者：
Reig, Maria
Galle, Peter R.
Kudo, Masatoshi
Finn, Richard S.
Llovet, Josep M.
Schelman, William R.
Liang, Kun
Wang, Chunxiao
Widau, Ryan C.
Abada, Paolo
Zhu, Andrew X.
机构：
[1] Hosp Clin Barcelona, Barcelona Clin Liver Canc Grp, Liver Unit, IDIBAPS,CIBEREHD, Barcelona, Spain
[2] Univ Med Mainz, Mainz, Germany
[3] Kindai Univ, Fac Med, Osaka, Japan
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
544
引用
收藏
页数：2
相关论文
共 50 条
  • [21] REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
    Zhu, Andrew X.
    Kang, Yoon-Koo
    Yen, Chia-Jui
    Finn, Richard S.
    Galle, Peter R.
    Llovet, Josep M.
    Assenat, Eric
    Brandi, Giovanni
    Lim, Ho Yeong
    Pracht, Marc
    Rau, Kun-Ming
    Merle, Philippe
    Motomura, Kenta
    Ohno, Izumi
    Daniele, Bruno
    Shin, Dongbok
    Gerken, Guido
    Abada, Paolo
    Hsu, Yanzhi
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Ramucirumab (RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) Following First-Line Therapy with Sorafenib: Analyses from the Randomized Phase III REACH Study
    Barone, C.
    Brandi, G.
    Daniele, B.
    Villa, E.
    Leo, S.
    Di Fabio, F.
    Aprile, G.
    Colombo, M.
    Sobrero, A.
    Giannelli, G.
    Porta, C.
    Cabibbo, G.
    Zhu, A.
    Blanc, J.
    Okusaka, T.
    Chau, I.
    Abada, P.
    Yang, L.
    Pastorelli, D.
    ANNALS OF ONCOLOGY, 2015, 26 : 91 - 91
  • [23] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study
    De Toni, E. N.
    Finn, R. C.
    Yau, Chung Cheung T.
    Yen, C. -J.
    Hsu, C. -H.
    Chan, S. L.
    He, A. R.
    Galle, P.
    Trojan, J.
    Stirnimann, G.
    Baron, A.
    Acosta-Rivera, M.
    Goyal, L.
    Wang, C.
    Abada, P.
    Widau, R.
    Zhu, A. X.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 125 - 126
  • [24] Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial
    Ohkawa, Shinichi
    Okusaka, Takuji
    Kudo, Masatoshi
    Hatano, Etsuro
    Fujii, Hirofumi
    Masumoto, Akihide
    Furuse, Junji
    Wada, Yoshiyuki
    Ishii, Hiroshi
    Obi, Shuntaro
    Arai, Kuniaki
    Kawazoe, Seiji
    Yokosuka, Osamu
    Ikeda, Masafumi
    Ukai, Katsuaki
    Morita, Sojiro
    Asou, Hiroya
    Abada, Paolo B.
    Yang, Ling
    Zhu, Andrew X.
    ANNALS OF ONCOLOGY, 2015, 26 : 94 - 94
  • [25] A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
    Zhu, A. X.
    Galle, P. R.
    Kudo, M.
    Finn, R.
    Yang, L.
    Abada, P.
    Llovet, J. M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
    Zhu, Andrew X.
    Galle, Peter R.
    Kudo, Masatoshi
    Finn, Richard S.
    Yang, Ling
    Abada, Paolo
    Chang, Shao-Chun
    Llovet, Josep M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [27] A randomized, double-blind, placebo-controlled Phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
    Andrew, Zhu
    Peter, Galle
    Masatoshi, Kudo
    Richard, Finn
    Ling, Yang
    Paolo, Abada
    Josep, Llovet
    ANNALS OF ONCOLOGY, 2016, 27 : 83 - 83
  • [28] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2
    Finn, Richard S.
    Yau, Thomas
    Hsu, Chih-Hung
    De Toni, Enrico N.
    Goyal, Lipika
    Galle, Peter R.
    Qin, Shukui
    Rao, Sujata
    Sun, Fangfang
    Wang, Chunxiao
    Widau, Ryan C.
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [29] A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
    Zhu, Andrew X.
    Galle, Peter R.
    Kudo, Masatoshi
    Finn, Richard S.
    Yang, Ling
    Abada, Paolo
    Llovet, Josep M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.
    Llovet, Josep M.
    Singal, Amit G.
    Villanueva, Augusto
    Finn, Richard S.
    Kudo, Masatoshi
    Galle, Peter R.
    Wang, Chunxiao
    Widau, Ryan C.
    Gugel, Elena Gonzalez
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345